Page 3 - Marek Ciszewski News Today

FinancialContent fully hosted finance channel

–  YUSIMRY™ will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company  – –  YUSIMRY will be available on costplusdrugs.com... | June 1, 2023

–  YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company  – –  YUSIMRY will be available on...

– UDENYCA® AI is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home – –... | May 22, 2023

REDWOOD CITY, Calif., May 16, 2023 -- Coherus BioSciences, Inc. today announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of... | May 16, 2023

Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Q1 2023 Earnings Call. Please be advised that today’s conference is being recorded.

– UDENYCA® autoinjector approved and ready for May 2023 launch –– CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 activation... | May 8, 2023

Operator: Thank you for standing by, and welcome to Coherus Biosciences Fourth Quarter and Fiscal Year 2022 Earnings Conference Call.

- Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with toripalimab plus chemotherapy significantly prolongs survival in patients with advanced NPC - SHANGHAI, China

Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential...